Reliq Health Technologies Inc. (RQHTF) Named #1 2018 TSX Venture 50TM Performer, and Reaches 10,000 Patients

“We are honoured to have been recognized as the #1 technology stock in the TSX Venture 50™,” said Dr. Lisa Crossley, CEO of Reliq Health. “I want to thank the team at Reliq Health for their hard work, dedication and passionate commitment to building a business aimed at fundamentally disrupting the current model for healthcare.  We also want to thank our shareholders, who have been so supportive of Reliq’s mission to reduce healthcare costs by improving health outcomes and access to care.”

The TSX Venture 50 acknowledges the top 10 performing companies listed on the TSX Venture Exchange in five industry sectors: mining, oil & gas, clean technology & life sciences, diversified industries, and technology. The winners are selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. The TSXV created a video profile on Reliq and other 2018 TSX Venture 50™ winners, available at www.tsx.com/venture50.

Additionally, the company is pleased to announce that it now has 10,000 patients live on its iUGO Care chronic care management, remote patient monitoring and telemedicine platform.

Reliq’s iUGO Care digital health solution provides high quality virtual care in the community by creating a “virtual hospital ward” within the patient’s home, automatically collecting vital signs and encouraging and tracking medication adherence. iUGO Care’s unique interactive voice technology provides patients with audible alerts and reminders to take their medications, collect their vitals using Bluetooth-enabled monitoring devices and perform prescribed rehab or fitness activities.  iUGO Care’s two-way voice hub provides voice-activated access to patient education content, empowering patients and family members to proactively manage complex chronic conditions.  Reliq’s iUGO Care cloud platform instantly alerts the clinical care team if a patient develops key warning signs, allowing clinicians to intervene before a health crisis occurs, preventing costly and disruptive hospital readmissions and ER visits.

ON BEHALF OF THE BOARD

“Dr. Lisa Crossley”

CEO and Director

For further information contact:

Renmark Financial Communications Inc. 
Laura Welsh: lwelsh@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

or CORE Capital Partners at 604-566-9233 or investors@ccpartnersinc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws.  All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company“) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.